On March 4 2026, the U.S. Food and Drug Administration issued an Establishment Inspection Report for Dr. Reddy’s Laboratories’ Srikakulam formulations facility, classifying the outcome as Voluntary Action Indicated (VAI) and closing the inspection under 21 CFR 20.64(D)(3). The report noted observations that the company must address, but no enforcement action or warning letter was issued.
The VAI classification indicates that the FDA identified objectionable conditions or practices that are not severe enough to warrant immediate enforcement. The public release did not disclose the specific observations, but the company is required to implement corrective actions to maintain compliance and avoid future enforcement actions.
This inspection followed a prior GMP and Pre‑Approval Inspection that Dr. Reddy’s disclosed on December 12 2025. Earlier inspections at the same site included a Form 483 with seven observations in July 2025, and a VAI classification at the Hyderabad API facility in November 2024. The pattern of inspections underscores the company’s ongoing regulatory scrutiny across its manufacturing network.
While the VAI outcome does not directly affect product approvals or market access, it signals that the Srikakulam facility remains operational and compliant. Implementing corrective actions is essential for sustaining the facility’s eligibility to supply finished dosage forms to the U.S. market and to support the company’s broader product portfolio.
Dr. Reddy’s recently reported Q3 FY26 results: net profit of ₹1,209.8 crore, revenue of ₹8,726.8 crore, and a gross margin of 53.6% versus 58.7% in the prior year. North American revenue declined due to reduced Lenalidomide sales, while the company’s core branded and nicotine replacement therapy (NRT) segments drove growth. The regulatory update is a factor in maintaining operational stability amid these financial dynamics.
Co‑Chairman and Managing Director G V Prasad noted that growth in the quarter was driven by momentum in branded markets and steady contributions from the NRT portfolio, which helped offset the decline in U.S. Lenalidomide sales. He emphasized the company’s focus on strengthening its core business, advancing key pipeline assets, driving productivity, and pursuing business development initiatives, all of which align with the need for robust regulatory compliance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.